000128951 001__ 128951
000128951 005__ 20240228143359.0
000128951 0247_ $$2doi$$a10.1080/15592294.2015.1137414
000128951 0247_ $$2pmid$$apmid:26786582
000128951 0247_ $$2pmc$$apmc:PMC4846111
000128951 0247_ $$2ISSN$$a1559-2294
000128951 0247_ $$2ISSN$$a1559-2308
000128951 0247_ $$2altmetric$$aaltmetric:5022330
000128951 037__ $$aDKFZ-2017-04963
000128951 041__ $$aeng
000128951 082__ $$a610
000128951 1001_ $$aKostareli, Efterpi$$b0
000128951 245__ $$aGene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.
000128951 260__ $$aAustin, Tex.$$bLandes Bioscience$$c2016
000128951 3367_ $$2DRIVER$$aarticle
000128951 3367_ $$2DataCite$$aOutput Types/Journal article
000128951 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1522135899_11164
000128951 3367_ $$2BibTeX$$aARTICLE
000128951 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128951 3367_ $$00$$2EndNote$$aJournal Article
000128951 520__ $$aInfection with high-risk types of human papilloma virus (HPV) is currently the best-established prognostic marker for head and neck squamous cell carcinoma (HNSCC), one of the most common and lethal human malignancies worldwide. Clinical trials have been launched to address the concept of treatment de-escalation for HPV-positive HNSCC with the final aim to reduce treatment related toxicity and debilitating long-term impacts on the quality of life. However, HPV-related tumors are mainly restricted to oropharyngeal SCC (OPSCC) and there is an urgent need to establish reliable biomarkers for all patients at high risk for treatment failure. A patient cohort (n = 295) with mainly non-OPSCC (72.9%) and a low prevalence of HPV16-related tumors (8.8%) was analyzed by MassARRAY to determine a previously established prognostic methylation score (MS). Kaplan-Meier revealed a highly significant correlation between a high MS and a favorable survival for OPSCC (P = 0.0004) and for non-OPSCC (P<0.0001), which was confirmed for all HNSCC by multivariate Cox regression models (HR: 9.67, 95% CI [4.61-20.30], P<0.0001). Next, we established a minimal methylation signature score (MMSS), which consists of ten most informative of the originally 62 CpG units used for the MS. The prognostic value of the MMSS was confirmed by Kaplan-Meier analysis for all HNSCC (P<0.0001) and non-OPSCC (P = 0.0002), and was supported by multivariate Cox regression models for all HNSCC (HR: 2.15, 95% CI [1.36-3.41], P = 0.001). In summary, the MS and the MMSS exhibit an excellent performance as prognosticators for survival, which is not limited by the anatomical site, and both could be implemented in future clinical trials.
000128951 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000128951 588__ $$aDataset connected to CrossRef, PubMed,
000128951 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000128951 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$udkfz
000128951 7001_ $$aZucknick, Manuela$$b2
000128951 7001_ $$0P:(DE-HGF)0$$aBaboci, Lorena$$b3
000128951 7001_ $$aWichmann, Gunnar$$b4
000128951 7001_ $$0P:(DE-He78)d84ca2cd7f160904c387ee699735076c$$aHolzinger, Dana$$b5$$udkfz
000128951 7001_ $$aMücke, Oliver$$b6
000128951 7001_ $$0P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aPawlita, Michael$$b7$$udkfz
000128951 7001_ $$aDel Mistro, Annarosa$$b8
000128951 7001_ $$aBoscolo-Rizzo, Paolo$$b9
000128951 7001_ $$aDa Mosto, Maria Cristina$$b10
000128951 7001_ $$aTirelli, Giancarlo$$b11
000128951 7001_ $$aPlinkert, Peter$$b12
000128951 7001_ $$aDietz, Andreas$$b13
000128951 7001_ $$0P:(DE-He78)4301875630bc997edf491c694ae1f8a9$$aPlass, Christoph$$b14$$udkfz
000128951 7001_ $$0P:(DE-He78)ff4024f7bc236e7897d9c18ee19c451f$$aWeichenhan, Dieter$$b15$$eLast author$$udkfz
000128951 7001_ $$0P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aHess, Jochen$$b16$$eLast author$$udkfz
000128951 773__ $$0PERI:(DE-600)2248598-3$$a10.1080/15592294.2015.1137414$$gVol. 11, no. 1, p. 61 - 73$$n1$$p61 - 73$$tEpigenetics$$v11$$x1559-2308$$y2016
000128951 909CO $$ooai:inrepo02.dkfz.de:128951$$pVDB
000128951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000128951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000128951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d84ca2cd7f160904c387ee699735076c$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000128951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d99bad949ba3ae93859eedae5ac266da$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000128951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4301875630bc997edf491c694ae1f8a9$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000128951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ff4024f7bc236e7897d9c18ee19c451f$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000128951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000128951 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000128951 9141_ $$y2016
000128951 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEPIGENETICS-US : 2015
000128951 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128951 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128951 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128951 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128951 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128951 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128951 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128951 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128951 9201_ $$0I:(DE-He78)F020-20160331$$kF020$$lMolekulare Diagnostik Oncogener Infektionen$$x0
000128951 9201_ $$0I:(DE-He78)C010-20160331$$kC010$$lEpigenomik und Krebsrisikofaktoren$$x1
000128951 9201_ $$0I:(DE-He78)G405-20160331$$kG405$$lMolekulare Grundlagen von HNO-Tumoren$$x2
000128951 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x3
000128951 980__ $$ajournal
000128951 980__ $$aVDB
000128951 980__ $$aI:(DE-He78)F020-20160331
000128951 980__ $$aI:(DE-He78)C010-20160331
000128951 980__ $$aI:(DE-He78)G405-20160331
000128951 980__ $$aI:(DE-He78)C060-20160331
000128951 980__ $$aUNRESTRICTED